Allodynic Therapeutics, LLC Email Format
Pharmaceutical ManufacturingUnited States2-10 Employees
Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migraine. Both naltrexone and acetaminophen individually can simultaneously reduce physical and emotional pain, potentially enhancing treatment outcomes. Naltrexone-acetaminophen U.S. patents extend to 2037.